פרופ' משה ענבר

קלינים הוראה אמריטוס
פרופ' משה ענבר
טלפון חיצוני: 03-6972066
פקס: 03-6974828

קורות חיים

Education:

Professor (Clinical) Sackler Faculty of Medicine

 

Academic Experience:

Professor, Sackler Faculty of Medicine

1997    -    Director Division of Oncology, Tel Aviv Sourasky Medical Center

תחומי מחקר

Research Areas:

Breast Cancer – adjuvant and metastatic

Hormonal therapy in Breast Cancer

Biologics in Adjuvant and Metastatic Breast Cancer

 

Steering Committees of – International Studies

1) ATLAS – Academic International Study comparing 5 years of Tamoxifen to 10 years of

     Tamoxifen in the Adjuvant setting.

2) HERA – Adjuvant Herceptin (sponsored by ROCHE)

3) ALTTO – Adjuvant Herceptin and Lapatinib in Breast Cancer (sponsored by GSK)

4) TURANDOT – International CECOG Study comparing Avastin + Taxol to Avastin +

    Xeloda in First line Metastatic Breast Cancer (sponsored by ROCHE)

פרסומים

List of Publications: (2008 – 2012)

 

1)   Adjuvant chemotherapy in oestrogen-receptor poor breast cancer: patient level meta-analysis of

   randomized trials.

Early Breast Cancer Trialists Collaborative (EBCTCG).

Lancet 2008: 371: 29-40

 

2) Tamar Safra MD, Julia Greenberg MD, Ilan G. Ron MD, Rami Ben-Yosef MD , Moshe Inbar MD,

  David Sarid MD and Neora Yaal-Hahoshen MD.

  "Fulvestrant in Heavily Pretreated Metastatic Breast Cancer – Is it still effective as a very advanced line of

  treatment?"

  IMAJ  27/225 2008: 10:00-00

 

  3) Benjamin W. Corn, Isaiah D. Wexler, Mohan Suntharalingam, Moshe Inbar, Walter J. Curran Jr.

   "Globalization of the Radiation Therapy Oncology Group: Implementation of a Model for Service 

   Expansion and Public Health Improvement".

   Journal of Clinical Oncology, Vol 26, No 7 (March 1), 2008: pp 1160-1166.

 

4) Ravit Geva MD, Irina Jiveliouk MD, Moshe Inbar MD, Isaac Meller MD, Eitan Friedman MD, PhD and

     Ofer Merimsky MD, MOncol.

     The Co-occurrence of Breast Cancer and Soft Tissue Sarcoma in a Single Cohort Series.

     American Journal of Clinical Oncology. Volume 31, Number 6, December 2008.

 

5)  Jiveliuk I, Corn B.W., Inbar M, Merimsky O: Ductal carcinoma in situ (DCIS) of the breast in Israeli

      women treated by breast conserving surgery followed by radiation therapy. Oncology 76:30-35, 2009.

 

6)  Corn B.W., Shabtai E., Merimsky O., Inbar M., Rosenbaum E., Meirovitz A., Wexler I.D.:

Do oncologists engage in bereavement practices? A survey of the Israeli Society of Clinical Oncology and

Radiotherapy (ISCORT). The Oncologist, 15: 317-326, 2010.

 

 7)  Prof. E. Even-Sapir MD, Prof. M. Inbar

   Department of Nuclear Medicine and Division of Oncology, Tel Aviv Sourasky Medical Center, Sackler  

   School of Medicine, Tel Aviv University, Tel Aviv – Israel.

   "PET in women with high risk for breast or ovarian cancer".

   The Lancet Oncology, July 7, 2010. DOI:10.1016/S1470-2045.

 

 8)   Yavetz D., Corn B., Matsevsky D., Ben Josef R., Soyfer V., Inbar M., Ron I., Schifter D.,: Improved

         treatment of the breast and supraclavicular fossa based on a simple geometric principle. Med Dosim,

        36: 434-439, 2011.

 

9)    Christina Davies Hongchao Pan, Jon Godwin, Richard Gray, Rodrigo Arriagada, Vinod Raina, Mirta braham,

  Victor Hugo Medeiros Alencar, Atef Badran, Xavier Bonfill, Joan Bradbury, Michael Clarke, Rory Collins,

  Susan Davis, Antonella Delmestri, John Forbes, Peiman Haddad, Ming-Feng Hou, Moshe Inbar, Hussein

  haled  Joanna Kielanowska, Wing-Hong Kwan, Beela S Mathew, Bettina Muller, Antonio Nicolucci, Octavio   

  Peralta, Fany Pernas, Lubos Petruzelka, Tadeusz Pienkowski, Balarishnan Rajan, Maryna T Rubach, Sera

  Tort, Gerard  Urrutia, Miriam Valentini, Yaochen Wang, Richard Peto, for the Adjuvant Tamoxifen:

  Longer Against Shorter (ATLAS) Collaborative Group.

  "Effects of adjuvant tamoxifen continued for 10 years versus discontinuation at 5 years for women with

  oestrogen receptor-positive breast cancer during the first and the second decade after diagnosis (ATLAS):  

  a randomized trial".

  The Lancet, vol 380, 5 December 2012

 

10) "Quality of life (QoL) results from  the TURANDOT trial comparing two bevacizumab (BEV) – containing

       regimens as first line treatment for HER2 – negative metastatic breast cancer (mBC)."

 Lang I, Inbar MJ, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Ahlers S, Brodowicz T, Zielinski C,

 National Institute of Oncology, Budapest Hungary, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel,

 University of Szeged, Hungary, Paracelsus Medical University, Salzburg, Austria; Institute of Oncology,

 Sarajevo, Bosnia and Herzegowina; Rabin Medical Center, Petah-Tikva, Israel; Sheba Medical Center,  

 Ramat Gan Israel, IST GmbH Mannheim, Mannheim Germany, Medical University of Vienna and Central

 European Cooperative Oncology Group (CECOG), Vienna Austria.

 CTRC-AACR San Antonio Breast Cancer Symposium

 Cancer Res, 72(24 Suppl.) December 15, 2012.

אוניברסיטת תל-אביב, ת.ד. 39040, תל-אביב 6997801
UI/UX Basch_Interactive